EGFR and neoplasm: Since PDOs are also reliable platforms for testing drug efficacy and predicting patient drug response [30, 31], we evaluated the expression of HER-2 and EGFR as cell surface-associated tumour biomarkers to identify the most suitable candidate therapeutic targets in this specific case.